Loading data for AIM — first visit, this takes a few seconds.
AIM ImmunoTech Inc. (AIM): cotización, análisis y datos
Estás viendo el resumen gratuito
Crea una cuenta gratuita para abrir las finanzas, las opciones, las previsiones y el resto de este valor.
Valor intrínseco
Ver planes →Pronóstico del analista
Previsiones bursátiles →Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | — | n/a | n/a |
| EPS | -$0.43 | -$0.31 | +88.32% |
Métricas
- Precio de compra
- 0.19
- Ingresos (TTM)
- 95K
- Beneficio neto (TTM)
- -14.3M
- 1.19
- -0.71
- n/a
- -0.51
- P/B (TTM)
- 0.71
- P/S (TTM)
- 79.41
- Fecha de resultados
- n/a
- Precio de venta
- 0.19
- Volumen
- 667,990
- Volumen medio (20D)
- 4,747,853
- Abierto
- 0.19
- Anterior Cerrar
- 0.19
- Rango del día
- 0.19 - 0.19
- Rango de 52 semanas
- 0.17 - 2.79
- analista
- n/a
- Precio objetivo
- n/a
- Dividendos
- n/a
- Fecha ex dividendo
- n/a
Acerca de AIM ImmunoTech Inc.
Ver perfil →AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
Industria Biotechnology
Sector Healthcare
IPO Fecha Jul 12, 1996
Empleados 19
Bolsa de Valores NYSE American
Símbolo bursátil AIM
Sitio web https://aimimmuno.com